


What is claimed is:

1. A method for treating a CNS disorder or impaired cognitive performance in a subject comprising administering to said subject in need thereof an effective amount of a pharmaceutical composition comprising a compound or a stereoisomer, pharmaceutically acceptable salt, solvate or polymorph thereof according to the structure:



wherein:

R^1 and R^2 are independently selected from H, C_1 - C_3 alkyl, F, Cl, Br, I, OH, $O(C_1-C_6)$ alkyl, $O-C(=O)-(C_1-C_6)$ alkyl or $C(=O)-O-(C_1-C_6)$ alkyl;

R^3 is H or a C_1 - C_6 alkyl group;

R^4 , R^5 , R^6 , R^7 and R^8 are independently selected from H, C_1 - C_6 alkyl, F, Cl, Br, I, OH, $-(CH_2)_nO(C_1-C_6)$ alkyl, $-(CH_2)_nO-C(=O)-(C_1-C_6)$ alkyl or $-(CH_2)_n C(=O)-O-(C_1-C_6)$ alkyl;

R^9 and R^{10} are independently H, C_1 - C_6 alkyl or together form a $-(CH_2)_m-$ group to produce a 5-7-membered ring;


n is from 0 to 5;

m is from 1 to 3;

and A^- is a pharmaceutically acceptable anion of a pharmaceutical salt, which forms a salt with the quaternized amine group, optionally in combination with a pharmaceutically acceptable carrier additive or excipient.

2. A method of claim 1 wherein R^1 and R^2 are both OCH_3 groups, R^3 is a CH_3 group, R^4 , R^5 , R^6 , R^7 and R^8 are each H, R^9 and R^{10} are each H, CH_3 or together form a $-CH_2-$ group to produce a five-membered ring;
and A^- is Cl^- , citrate or phosphate.
3. A method of claim 2, wherein R^9 and R^{10} together form a $-CH_2-$ group to produce a five-membered ring.
4. A method of claim 1, wherein the CNS disorder is a bipolar disorder.
5. A method of claim 1, wherein the CNS disorder is an anxiety disorder.
6. A method of claim 1, wherein the CNS disorder is stress-induced.
7. A method of claim 1, wherein the CNS disorder is attention deficit hyperactivity disorder (ADHD).
8. A method of claim 1, wherein the CNS disorder is schizophrenia.
9. A method of claim 1, wherein said subject is treated for impaired cognitive performance.
10. A method of claim 1, wherein the CNS disorder is associated with enhanced PKC activity.
11. A method of claim 1, wherein the impaired cognitive performance is induced or exacerbated by stress.
12. A method of claim 1, wherein the pharmaceutical composition is administered orally and the subject is a human.

13. A method of claim 9, wherein the pharmaceutical composition is administered orally and the subject is a human.
14. A method of claim 10, wherein the pharmaceutical composition is administered orally and the subject is a human.
15. A pharmaceutical composition comprising an effective amount of a compound or a stereoisomer, pharmaceutically acceptable salt, solvate or polymorph thereof according to the structure:



wherein:

R^1 and R^2 are independently selected from H, C_1 - C_3 alkyl, F, Cl, Br, I, OH, $O(C_1$ - C_6 alkyl), $O-C(=O)-(C_1$ - C_6 alkyl) or $C(=O)-O-(C_1$ - C_6 alkyl);

R^3 is H or a C_1 - C_6 alkyl group;

R^4 , R^5 , R^6 , R^7 and R^8 are independently selected from H, C_1 - C_6 alkyl, F, Cl, Br, I, OH, $-(CH_2)_nO(C_1$ - C_6 alkyl), $-(CH_2)_nO-C(=O)-(C_1$ - C_6 alkyl) or $-(CH_2)_n C(=O)-O-(C_1$ - C_6 alkyl);

R^9 and R^{10} are independently H, C_1 - C_6 alkyl or together form a $-(CH_2)_m-$ group to produce a 5-7-membered ring;

n is from 0 to 5;

m is from 1 to 3;

and A^- is a pharmaceutically acceptable anion of a pharmaceutical salt, which forms a salt with the quaternized amine group, in combination with a pharmaceutically acceptable carrier, additive or excipient.

16. A composition of claim 14 wherein R^1 and R^2 are both OCH_3 groups, R^3 is a CH_3 group, R^4 , R^5 , R^6 , R^7 and R^8 are each H, R^9 and R^{10} are each H, CH_3 or together form a $-CH_2-$ group to produce a five-membered ring;
and A^- is Cl^- , citrate or phosphate.
17. A composition of claim 15, wherein R^9 and R^{10} together form a $-CH_2-$ group to produce a five-membered ring.
18. A method of treatment comprising administering to a subject suffering from manic episodes associated with enhanced PKC activity a therapeutically effective amount of a composition according to claim 15.
19. A method of claim 18, wherein the manic episodes are also stress induced.
20. A method comprising protecting a subject from developing a CNS disorder by administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 15.